Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
- DOI
- 10.1016/s2352-3026(26)00193-6
- Published
- 2026-09
- Container
- The Lancet Haematology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2352-3026-26-00193-6,
title = {Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial},
author = {David J Kuter and Waleed Ghanima and Nichola Cooper and Howard A Liebman and Lei Zhang and Yu Hu and Yoshitaka Miyakawa and Marie Luise Hütter-Krönke and Cristina Pascual-Izquierdo and Elisa Lucchini and Sylvain Audia and Matias Cordoba and Heidi Krenz and Mengjie Yao and Ahmed Daak},
year = {2026},
journal = {The Lancet Haematology},
doi = {10.1016/s2352-3026(26)00193-6},
url = {https://doi.org/10.1016/s2352-3026(26)00193-6}
}RIS
TY - JOUR TI - Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial AU - David J Kuter AU - Waleed Ghanima AU - Nichola Cooper AU - Howard A Liebman AU - Lei Zhang AU - Yu Hu AU - Yoshitaka Miyakawa AU - Marie Luise Hütter-Krönke AU - Cristina Pascual-Izquierdo AU - Elisa Lucchini AU - Sylvain Audia AU - Matias Cordoba AU - Heidi Krenz AU - Mengjie Yao AU - Ahmed Daak PY - 2026 JO - The Lancet Haematology DO - 10.1016/s2352-3026(26)00193-6 UR - https://doi.org/10.1016/s2352-3026(26)00193-6 ER -
APA
Kuter, D. J., Ghanima, W., Cooper, N., Liebman, H. A., Zhang, L., Hu, Y., Miyakawa, Y., Hütter-Krönke, M. L., Pascual-Izquierdo, C., Lucchini, E., Audia, S., Cordoba, M., Krenz, H., Yao, M., & Daak, A. (2026). Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(26)00193-6
Source records
- crossref · retrieved 2026-09-26T21:08:09.591Z